Atricure

Morgan Keegan has published a report on AtriCure (NASDAQ: ATRC) after a grant to develop minimally invasive surgical technology. In the report, Morgan Keenan comments, "We think AtriCure shares are currently traded near fair value. Using a 10-year DCF and EV/Sales, AtriCure shares appear fairly...